FDA-approved
Heart & blood
Eptifibatide
Evidence
FDA approved
Class
Glycoprotein IIb/IIIa inhibitor
KEY TAKEAWAY
Eptifibatide is a cyclic peptide that blocks platelet clumping. It is used for acute coronary syndrome and during stent procedures.
Written by the Veylo editorial team · Updated
November 2026
What it is
A cyclic peptide that blocks platelet aggregation
Approved for
Acute coronary syndrome and percutaneous coronary intervention
Key fact
Reduced death and heart attack in patients with acute coronary syndromes
Route
Intravenous infusion
Evidence strength
FDA approved
Eptifibatide, sold as Integrilin, is a small cyclic peptide designed after a protein in snake venom.
It blocks the glycoprotein IIb/IIIa receptor on platelets so they cannot stick together to form clots.
The FDA approved eptifibatide in 1998 for acute coronary syndrome and angioplasty.
Reducing clot-related events in unstable angina, heart attack and during stenting.
Bleeding is the most common problem. A drop in platelet count can occur and needs monitoring.
PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.